UK Markets closed
NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,377.10 -971.53 (-3.99%)
Novo Nordisk A/S (NVO)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 04:00PM EDT. Market open.
| Previous close | 104.05 |
| Open | 106.53 |
| Bid | 105.10 x 1000 |
| Ask | 108.12 x 1800 |
| Day's range | 106.35 - 108.19 |
| 52-week range | 78.71 - 122.16 |
| Volume | |
| Avg. volume | 1,521,222 |
| Market cap | 245.625B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 35.49 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.57 (1.48%) |
| Ex-dividend date | 25 Mar 2022 |
| 1y target est | N/A |
- Motley Fool
Why This FDA Approval Is a Game Changer for Eli Lilly
Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.
- Zacks
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
- Zacks
4 Large Drug Stocks to Watch as the Industry Recovers
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
© 2022 Yahoo. All rights reserved.
